Literature DB >> 26780458

Gastrin-Releasing Peptide Receptor Knockdown Induces Senescence in Glioblastoma Cells.

Pâmela Rossi Menegotto1,2, Patrícia Luciana da Costa Lopez1,3, Bárbara Kunzler Souza1,2, Caroline Brunetto de Farias1,4, Eduardo Cremonese Filippi-Chiela3,5, Igor Araújo Vieira6, Gilberto Schwartsmann1,7, Guido Lenz5, Rafael Roesler8,9.   

Abstract

Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, characterized by excessive cell proliferation, resistance to apoptosis, and invasiveness. Due to resistance to currently available treatment options, the prognosis for patients with GBM is very dismal. The activation of gastrin-releasing peptide receptors (GRPR) stimulates GBM cell proliferation, whereas GRPR antagonists induce antiproliferative effects in in vitro and in vivo experimental models of GBM. However, the role of GRPR in regulating other aspects of GBM cell function related to tumor progression remains poorly understood, and previous studies have not used RNA interference techniques as tools to examine GRPR function in GBM. Here, we found that stable GRPR knockdown by a lentiviral vector using a short hairpin interfering RNA sequence in human A172 GBM cells resulted in increased cell size and altered cell cycle dynamics consistent with cell senescence. These changes were accompanied by increases in the content of p53, p21, and p16, activation of epidermal growth factor receptors (EGFR), and a reduction in p38 content. These results increase our understanding of GRPR regulation of GBM cells and further support that GRPR may be a relevant therapeutic target in GBM.

Entities:  

Keywords:  Bombesin receptor; Brain tumor; Cell senescence; Gastrin-releasing peptide receptor; Glioblastoma; RNA interference

Mesh:

Substances:

Year:  2016        PMID: 26780458     DOI: 10.1007/s12035-016-9696-6

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  36 in total

Review 1.  Cellular senescence: putting the paradoxes in perspective.

Authors:  Judith Campisi
Journal:  Curr Opin Genet Dev       Date:  2010-11-17       Impact factor: 5.578

Review 2.  Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.

Authors:  D B Cornelio; R Roesler; G Schwartsmann
Journal:  Ann Oncol       Date:  2007-03-09       Impact factor: 32.976

3.  Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans.

Authors:  R E Carroll; K A Matkowskyj; S Chakrabarti; T J McDonald; R V Benya
Journal:  Am J Physiol       Date:  1999-03

4.  Human glioblastoma cell lines have neuropeptide receptors for bombesin/gastrin-releasing peptide.

Authors:  T W Moody; S Mahmoud; J Staley; L Naldini; D Cirillo; V South; S Felder; R Kris
Journal:  J Mol Neurosci       Date:  1989       Impact factor: 3.444

5.  Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR).

Authors:  Christoph Garbers; Fabian Kuck; Samadhi Aparicio-Siegmund; Kirstin Konzak; Mareike Kessenbrock; Annika Sommerfeld; Dieter Häussinger; Philipp A Lang; Dirk Brenner; Tak W Mak; Stefan Rose-John; Frank Essmann; Klaus Schulze-Osthoff; Roland P Piekorz; Jürgen Scheller
Journal:  Cell Cycle       Date:  2013-09-18       Impact factor: 4.534

6.  Gastrin-releasing peptide receptor expression in cervical cancer.

Authors:  Daniela Baumann Cornelio; Luise Meurer; Rafael Roesler; Gilberto Schwartsmann
Journal:  Oncology       Date:  2008-05-23       Impact factor: 2.935

7.  Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.

Authors:  Marianne Schrader de Oliveira; Giovana Cechim; Elisandra Braganhol; Daniel Garcia Santos; Luise Meurer; Cláudio Galvão de Castro; Algemir Lunardi Brunetto; Gilberto Schwartsmann; Gilberto Schwarstmann; Ana Maria Oliveira Battastini; Guido Lenz; Rafael Roesler
Journal:  J Neurooncol       Date:  2009-01-08       Impact factor: 4.130

8.  Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.

Authors:  J Pinski; A V Schally; G Halmos; K Szepeshazi; K Groot
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

Review 9.  Cancer stem cells and the biology of brain tumors.

Authors:  Debora Gazzana Flores; Pitia Flores Ledur; Ana Lucia Abujamra; Algemir Lunardi Brunetto; Gilberto Schwartsmann; Guido Lenz; Rafael Roesler
Journal:  Curr Stem Cell Res Ther       Date:  2009-12       Impact factor: 3.828

10.  Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas.

Authors:  Domenico Coppola; Lodovico Balducci; Dung-Tsa Chen; Andrey Loboda; Michael Nebozhyn; Aileen Staller; William J Fulp; William Dalton; Timothy Yeatman; Steven Brem
Journal:  J Geriatr Oncol       Date:  2014-09-11       Impact factor: 3.599

View more
  3 in total

1.  Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements.

Authors:  Lucia Baratto; Heying Duan; Riccardo Laudicella; Akira Toriihara; Negin Hatami; Valentina Ferri; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-02       Impact factor: 9.236

2.  Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells.

Authors:  Viviane Rösner Almeida; Igor Araujo Vieira; Marienela Buendia; André Tesainer Brunetto; Lauro J Gregianin; Algemir Lunardi Brunetto; Fábio Klamt; Caroline Brunetto de Farias; Ana Lucia Abujamra; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  Mol Neurobiol       Date:  2016-11-10       Impact factor: 5.590

Review 3.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.